Aspirinamine Hydrochloride

盐酸阿司匹林胺

Report date: 2025/03/31 10:52:58
NME

Base Information

Drug NameAspirinamine Hydrochloride
Drug Alias NameTF-0023TF0023
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCyclooxygenases inhibitorsPlatelet aggregation inhibitors
TargetsCyclooxygenases
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Ischemic StrokeMyocardial Infarction +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSouth AfricaMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShanghai Taifei'Er Biochemical Technology Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesTechfields IncShanghai Taifei'Er Biochemical Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsMyocardial InfarctionHeart FailureStroke +[4] 
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Ischemic Stroke

Other Information

ATC CodeN/A
Related LinksN/A